These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27632289)

  • 1. Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.
    Hainsworth JD; Murphy PB; Alemar JR; Daniel BR; Young RR; Yardley DA
    Breast Cancer Res Treat; 2016 Nov; 160(1):41-49. PubMed ID: 27632289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
    Schramm A; Friedl TW; Schochter F; Scholz C; de Gregorio N; Huober J; Rack B; Trapp E; Alunni-Fabbroni M; Müller V; Schneeweiss A; Pantel K; Meier-Stiegen F; Hartkopf A; Taran FA; Wallwiener D; Janni W; Fehm T
    Arch Gynecol Obstet; 2016 Feb; 293(2):271-81. PubMed ID: 26354331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
    Agelaki S; Kalykaki A; Markomanolaki H; Papadaki MA; Kallergi G; Hatzidaki D; Kalbakis K; Mavroudis D; Georgoulias V
    PLoS One; 2015; 10(6):e0123683. PubMed ID: 26083256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.
    Acevedo-Gadea C; Hatzis C; Chung G; Fishbach N; Lezon-Geyda K; Zelterman D; DiGiovanna MP; Harris L; Abu-Khalaf MM
    Breast Cancer Res Treat; 2015 Feb; 150(1):157-67. PubMed ID: 25687356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.
    Verschoor N; Bos MK; de Kruijff IE; Van MN; Kraan J; Drooger JC; Zuetenhorst JM; Wilting SM; Sleijfer S; Jager A; Martens JWM
    Breast Cancer Res Treat; 2024 May; 205(1):87-95. PubMed ID: 38291268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
    Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
    Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer.
    Cao S; Li Y; Li J; Li CF; Zhang W; Yang ZQ; Meng SD
    Oncol Rep; 2010 Feb; 23(2):423-8. PubMed ID: 20043103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.
    Munzone E; Nolé F; Goldhirsch A; Botteri E; Esposito A; Zorzino L; Curigliano G; Minchella I; Adamoli L; Cassatella MC; Casadio C; Sandri MT
    Clin Breast Cancer; 2010 Oct; 10(5):392-7. PubMed ID: 20920984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.
    Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V
    Breast Cancer Res; 2015 Aug; 17(1):113. PubMed ID: 26285572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells.
    Parsons HA; Macrae ER; Guo H; Li T; Barry WT; Tayob N; Wulf GM; Isakoff SJ; Krop IE
    JCO Precis Oncol; 2021 Nov; 5():896-903. PubMed ID: 34994617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
    Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
    Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
    Jacot W; Cottu P; Berger F; Dubot C; Venat-Bouvet L; Lortholary A; Bourgeois H; Bollet M; Servent V; Luporsi E; Espié M; Guiu S; D'Hondt V; Dieras V; Sablin MP; Brain E; Neffati S; Pierga JY; Bidard FC
    Breast Cancer Res; 2019 Nov; 21(1):121. PubMed ID: 31727113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.
    Krawczyk N; Neubacher M; Meier-Stiegen F; Neubauer H; Niederacher D; Ruckhäberle E; Mohrmann S; Hoffmann J; Kaleta T; Banys-Paluchowski M; Reinecke P; Esposito I; Janni W; Fehm T
    BMC Cancer; 2019 Nov; 19(1):1101. PubMed ID: 31718606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
    Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
    Wu F; McCuaig RD; Sutton CR; Tan AHY; Jeelall Y; Bean EG; Dai J; Prasanna T; Batham J; Malik L; Yip D; Dahlstrom JE; Rao S
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31238530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance.
    Li Y; Zhang X; Liu D; Gong J; Wang DD; Li S; Peng Z; Li Y; Wang X; Lin PP; Li M; Shen L
    Clin Cancer Res; 2018 Nov; 24(21):5261-5271. PubMed ID: 30012565
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.